Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

NCT04251156 on ClinicalTrials.gov · last registry update 2026-01-29

Finished 23 August 2022, after enrolling 375 people. Primary outcome, as filed: Change From Baseline in Body Weight (Percentage [%]). semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 375
Started: 2020-12-08
Primary completion: 2022-08-23 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Body Weight (Percentage [%])

Conditions studied

Overweight · Obesity · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.